Biophytis S.A. (BPTS) — AI Stock Analysis

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases. Their lead drug candidate, Sarconeos (BIO101), targets neuromuscular diseases and respiratory failure associated with COVID-19.

Company Overview

TL;DR:

Biophytis S.A. is a clinical-stage biotechnology firm developing therapeutics for age-related degenerative diseases, primarily through its Sarconeos (BIO101) drug candidate targeting sarcopenia, Duchenne muscular dystrophy, and COVID-19-related respiratory failure, positioning it within the competitive biotechnology landscape.

About BPTS

Biophytis S.A., founded in 2006 and headquartered in Paris, France, is a clinical-stage biotechnology company dedicated to developing therapeutics that address age-related degenerative processes. The company's core focus lies in identifying and activating key biological resilience pathways, aiming to protect against and counteract the multiple biological and environmental stresses that contribute to age-related diseases. Their lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for treating neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing Phase 2/3 clinical trials for the treatment of severe respiratory failure in patients suffering from COVID-19. In addition to Sarconeos, Biophytis is developing Macuneos (BIO201), another orally administered small molecule, designed for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis collaborates with AFM-Telethon for the development of Sarconeos (BIO101) in treating DMD, highlighting their commitment to partnerships in advancing therapeutic solutions.

Investment Thesis

Biophytis S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is currently tied to the successful clinical development and commercialization of Sarconeos (BIO101) and Macuneos (BIO201). Key value drivers include positive clinical trial results for Sarconeos in sarcopenia, DMD, and COVID-19-related respiratory failure. The ongoing Phase 2/3 study for Sarconeos in COVID-19 patients is a critical catalyst. Failure to achieve positive clinical outcomes or secure regulatory approvals could significantly impact the company's valuation. The company's relatively small size and limited financial resources also pose risks to its long-term viability.

Industry Context

Biophytis S.A. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. The company focuses on age-related diseases, a growing market due to the increasing global aging population. Competitors include companies like AFMD, ARAV, EIGRQ, FRES and IDRA, which are developing therapies for similar indications. The biotechnology industry is driven by innovation and the ability to bring novel therapies to market, making clinical trial success a critical factor for company valuation and growth.

Biotechnology

Healthcare

Growth Opportunities

Sarconeos (BIO101) for Sarcopenia: The global sarcopenia market is projected to reach billions of dollars by 2030, driven by the aging population and increasing awareness of muscle loss. Positive Phase 3 trial results for Sarconeos in sarcopenia could lead to regulatory approval and commercialization, providing a significant revenue stream for Biophytis. The timeline for potential market entry is dependent on trial outcomes and regulatory review, but could be within the next 3-5 years.
Sarconeos (BIO101) for Duchenne Muscular Dystrophy (DMD): DMD is a rare genetic disorder with limited treatment options. Sarconeos has the potential to address the underlying muscle degeneration in DMD patients. The company's collaboration with AFM-Telethon provides access to expertise and resources for DMD drug development. Market size is smaller than sarcopenia, but the unmet need and potential for orphan drug designation could provide pricing advantages.
Sarconeos (BIO101) for COVID-19-related Respiratory Failure: The COVID-19 pandemic has created a significant need for therapies to treat severe respiratory failure. Sarconeos is currently in Phase 2/3 clinical trials for this indication. Positive results could lead to rapid regulatory approval and commercialization, providing a near-term revenue opportunity for Biophytis. However, the evolving nature of the pandemic and the emergence of new variants pose uncertainties.
Macuneos (BIO201) for Dry Age-Related Macular Degeneration (AMD): Dry AMD is a leading cause of vision loss in the elderly. Macuneos is being developed to address the underlying retinal degeneration in dry AMD patients. The dry AMD market is large and growing, with limited treatment options available. Successful clinical development and commercialization of Macuneos could provide a significant long-term growth opportunity for Biophytis.
Expansion of Pipeline through Strategic Partnerships: Biophytis can leverage its expertise in age-related diseases to expand its pipeline through strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships could provide access to new drug candidates, technologies, and markets. The company's collaboration with AFM-Telethon demonstrates its ability to forge successful partnerships. Identifying and securing additional partnerships will be crucial for long-term growth and diversification.

Biophytis S.A. is a clinical-stage company, meaning its value is heavily dependent on successful clinical trial outcomes.
Sarconeos (BIO101) is the lead drug candidate, targeting multiple indications including sarcopenia, Duchenne muscular dystrophy (DMD), and COVID-19-related respiratory failure.
Macuneos (BIO201) is being developed for retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease, expanding the company's therapeutic focus.
The company has a collaboration agreement with AFM-Telethon for the development of Sarconeos (BIO101) for the treatment of DMD.
The company's market capitalization is $0.00B, reflecting its early stage and the inherent risks associated with biotechnology investments.

What They Do

Develop therapeutics for age-related degenerative diseases.
Focus on activating key biological resilience pathways.
Develop orally administered small molecule drugs.
Target neuromuscular diseases like sarcopenia and Duchenne muscular dystrophy.
Develop treatments for retinal diseases like dry age-related macular degeneration.
Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
Collaborate with research institutions and patient organizations.

Business Model

Develop and patent novel therapeutic compounds.
Conduct preclinical and clinical trials to demonstrate safety and efficacy.
Seek regulatory approval from agencies like the FDA and EMA.
Potentially commercialize products directly or through partnerships.
Generate revenue through product sales, licensing agreements, and research grants.

Patients suffering from age-related diseases such as sarcopenia, Duchenne muscular dystrophy, and dry age-related macular degeneration.
Healthcare providers who prescribe and administer Biophytis's therapeutics.
Pharmaceutical companies that may partner with Biophytis for drug development and commercialization.
Research institutions and patient organizations that collaborate with Biophytis on clinical trials and research.

Proprietary drug candidates with patent protection.
Expertise in age-related diseases and biological resilience pathways.
Clinical trial data demonstrating safety and efficacy.
Collaboration agreements with research institutions and patient organizations.
Potential for orphan drug designation for certain indications.

Catalysts

Upcoming: Phase 3 clinical trial results for Sarconeos (BIO101) in sarcopenia.
Upcoming: Regulatory approval decisions for Sarconeos (BIO101) in sarcopenia, DMD, or COVID-19-related respiratory failure.
Ongoing: Enrollment and progress in clinical trials for Macuneos (BIO201) in dry AMD.
Ongoing: Potential strategic partnerships with other biotechnology and pharmaceutical companies.

Risks

Potential: Clinical trial failures for Sarconeos (BIO101) or Macuneos (BIO201).
Potential: Regulatory delays or rejection of marketing applications.
Ongoing: Competition from established pharmaceutical companies.
Ongoing: Limited financial resources and need for additional funding.
Potential: Patent expiration and generic competition.

Strengths

Novel drug candidates targeting age-related diseases.
Focus on biological resilience pathways.
Collaboration with AFM-Telethon.
Potential for orphan drug designation.

Weaknesses

Clinical-stage company with no approved products.
Limited financial resources.
High risk of clinical trial failure.
Dependence on successful development of Sarconeos and Macuneos.

Opportunities

Growing market for age-related disease therapeutics.
Potential for strategic partnerships.
Expansion of pipeline through new drug candidates.
Fast-track regulatory approval for certain indications.

Threats

Competition from established pharmaceutical companies.
Regulatory hurdles and delays.
Patent expiration.
Adverse events in clinical trials.

Competitors & Peers

Affimed N.V. — Focuses on cancer immunotherapy. — (AFMD)
Aravive, Inc. — Develops therapies for cancer and fibrotic diseases. — (ARAV)
Eiger BioPharmaceuticals, Inc. — Develops therapies for serious diseases with unmet medical needs. — (EIGRQ)
Fresenius SE & Co. KGaA — Diversified healthcare company with a broad range of products and services. — (FRES)
Idera Pharmaceuticals, Inc. — Focuses on developing therapies for immuno-oncology and rare diseases. — (IDRA)

Key Metrics

Volume: 0
MoonshotScore: 44/100

Company Profile

CEO: Stanislas Veillet
Headquarters: Paris, FR
Employees: 22
Founded: 2021

AI Insight

AI analysis pending for BPTS

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does Biophytis S.A. do?

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics for age-related degenerative diseases. Their primary focus is on identifying and activating key biological resilience pathways to combat the effects of aging. The company's lead drug candidate, Sarconeos (BIO101), is being developed for the treatment of neuromuscular diseases like sarcopenia and Duchenne muscular dystrophy, as well as severe respiratory failure associated with COVID-19. They are also developing Macuneos (BIO201) for retinal diseases such as dry age-related macular degeneration.

What do analysts say about BPTS stock?

As a clinical-stage biotechnology company, Biophytis S.A. is subject to significant volatility based on clinical trial outcomes and regulatory milestones. Analyst sentiment is largely dependent on the perceived probability of success for Sarconeos (BIO101) and Macuneos (BIO201). Key valuation metrics include potential peak sales for these drug candidates, discounted by the probability of success and time to market. Given its current market cap of $0.00B, successful clinical trials and regulatory approvals could lead to significant upside, while failures could result in substantial downside risk.

What are the main risks for BPTS?

The primary risks for Biophytis S.A. are related to the inherent uncertainties of drug development. Clinical trial failures for Sarconeos (BIO101) or Macuneos (BIO201) would significantly impact the company's valuation. Regulatory delays or rejection of marketing applications also pose significant risks. Competition from larger, more established pharmaceutical companies with greater resources is another concern. Additionally, the company's limited financial resources and need for additional funding could dilute existing shareholders or hinder development efforts.

Is BPTS a good investment right now?

Use the AI score and analyst targets on this page to evaluate Biophytis S.A. (BPTS). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for BPTS?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Biophytis S.A. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find BPTS financial statements?

Biophytis S.A. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.

What do analysts say about BPTS?

Analyst consensus targets and ratings for Biophytis S.A. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.

How volatile is BPTS stock?

Check the beta and historical price range on this page to assess Biophytis S.A.'s volatility relative to the broader market.